A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA).
This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide.
There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Inclusion Criteria:
Exclusion Criteria:
abbvieclinicaltrials@abbvie.com844-663-3742
Jonesboro, Arkansas 72401, United States
Beverly Hills, California 90211, United States
Chula Vista, California 91910, United States
Huntington Beach, California 92648-5994, United States
Upland, California 91786, United States
Fort Collins, Colorado 80528, United States
Avon Park, Florida 33825, United States
Clearwater, Florida 33765, United States
Greenacres City, Florida 33467, United States
Margate, Florida 33063, United States
Tampa, Florida 33606, United States
Chicago, Illinois 60611, United States
Lake Charles, Louisiana 70605, United States
Grand Blanc, Michigan 48439, United States
Albuquerque, New Mexico 87102, United States
Great Neck, New York 11021, United States
Charlotte, North Carolina 28204, United States
Charlotte, North Carolina 28211-1064, United States
Middleburg Heights, Ohio 44130, United States
Duncansville, Pennsylvania 16635, United States
Allen, Texas 75013, United States
Carrollton, Texas 75007, United States
Houston, Texas 77401, United States
Southlake, Texas 76092, United States
Gillette, Wyoming 82718, United States
Sherbrooke, Quebec J1G 2E8, Canada
Saskatoon, Saskatchewan S7H 0P4, Canada
Veszprém, Fejér 8200, Hungary
Budapest, 1023, Hungary
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-068, Poland
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-168, Poland
Krakow, Lesser Poland Voivodeship 31-011, Poland
Elblag, Warmian-Masurian Voivodeship 82-300, Poland
Olsztyn, Warmian-Masurian Voivodeship 10-117, Poland
Novi Sad, Juznobacki Okrug 21000, Serbia
Novi Sad, Juznobacki Okrug 21000, Serbia
George, Western Cape 6529, South Africa
Cheonan-si, Chungcheongnam-do 31151, South Korea
619-334-4735
813-870-1292
814-693-0300
713-487-8680
832-234-1023
972-288-2600
787-722-0662
787-765-9034